A Study of DF6002 Alone and in Combination With Nivolumab
Dragonfly Therapeutics
Dragonfly Therapeutics
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Exelixis
University of Chicago
Replimune Inc.
Myeloid Therapeutics
Ohio State University Comprehensive Cancer Center
Novartis
Genentech, Inc.
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Bristol-Myers Squibb
H. Lee Moffitt Cancer Center and Research Institute
University of California, San Diego
Tesaro, Inc.
Nanobiotix
Memorial Sloan Kettering Cancer Center
Memgen, Inc.
DEKA Biosciences
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb
Exelixis
Compugen Ltd
Navire Pharma Inc., a BridgeBio company
Eli Lilly and Company
Molecular Templates, Inc.
Celgene
Ono Pharmaceutical Co. Ltd
Yale University
Pfizer
Biomica Ltd.
H. Lee Moffitt Cancer Center and Research Institute
Rutgers, The State University of New Jersey
Bayer
Roswell Park Cancer Institute
Fate Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
Tempest Therapeutics
Assistance Publique Hopitaux De Marseille
Fate Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
Second Affiliated Hospital, School of Medicine, Zhejiang University
Bristol-Myers Squibb
Alliance Foundation Trials, LLC.
Calithera Biosciences, Inc
Augusta University
Infinity Pharmaceuticals, Inc.
Five Prime Therapeutics, Inc.
Bristol-Myers Squibb